CORCEPT THERAPEUTICS I

30.39

25-June-24 15:59:59

15 minutes delayed

Stocks

-0.20

-0.65%

Today's range

30.39 - 31.46

ISIN

N/A

Source

NASDAQ

Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

06 May 2021 16:01:01 By Nasdaq GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

29 Apr 2021 16:05:01 By Nasdaq GlobeNewswire
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

15 Mar 2021 07:30:00 By Nasdaq GlobeNewswire
Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer

01 Mar 2021 16:05:00 By Nasdaq GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

23 Feb 2021 16:05:00 By Nasdaq GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

08 Feb 2021 16:05:00 By Nasdaq GlobeNewswire
Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call

01 Feb 2021 16:05:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
5
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.